Summary
GlobalData, the industry analysis specialist, has released a new report, "Schizophrenia-Drug Pipeline Analysis and Market Forecasts to 2015". The report is an essential source of information and analysis on the global schizophrenia market. The report identifies the key trends shaping and driving the global schizophrenia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global schizophrenia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
GlobalData estimated the global schizophrenia market to be valued at $15.9 billion in 2008. It is forecast to grow by 1.3% annually for the next seven years to reach $17.2 billion by 2015.

This low growth is primarily attributed to release of generics of some of the leading products as well as weak pipeline candidates. High incidence and prevalence rate of disease will act as a driver for the market growth; however this will not be able to compensate for restriction caused by barriers as they are stronger in impact. GlobalData analyzed that the global schizophrenia market is moderately served with current product options and significant scope available to new entrants that would capture value from underserved segments. 
GlobalData analyzed that the global schizophrenia market is heading toward static competitive landscape. As pipeline candidates are not offering clear clinical benefits compared to current products in term of prolonged remission and high safety profile, the launch of these molecules in near future will not be able to bring significant change in competitive landscape. Designing curable products with high safety profile is one of key challenges of this market and coming up with a product of high efficacy and safety profile will be proved to be a future blockbuster.

Scope
The scope of the report includes:
-Annualized global schizophrenia market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include dopamine serotonin receptor targetters, nicotinic acetylcholine receptors targetters, NK receptors targetters and NMDA receptors targetters.
-Analysis of the current and future market competition in the global schizophrenia market. Key market players covered are AstraZeneca PLC, Pfizer Inc., GSK, J&J and Merck & Co.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with schizophrenia.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global schizophrenia market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global schizophrenia market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global schizophrenia market landscape?-Identify, understand and capitalize.

Table of Contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Schizophrenia Market: Market Characterization
2.1 Overview
2.2 Schizophrenia Market Size
2.3 Schizophrenia Market Forecast and CAGR
2.4 Drivers and Barriers for Schizophrenia Market
2.4.1 Drivers for Schizophrenia Market
2.4.2 Barriers for Schizophrenia Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway
3 Schizophrenia Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in Schizophrenia Market
3.3.1 Zyprexa (olanzapine)
3.3.2 Abilify (aripiprazole)
3.3.3 Seroquel/Seroquel XR (quetiapine)
3.3.4 Geodon (ziprasidone)
3.3.5 Invega (paliperidone)
3.3.6 Serdolect (sertindole)
3.3.7 Fanapt (iloperidone)
3.3.8 Saphris (asenapine)
3.4 Key Takeaway
4 Schizophrenia Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytic Framework
4.3 Schizophrenia Therapeutics-Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
4.4.1 Staccato Loxapine, AZ-004 (Loxapine)
4.4.2 Lurasidone
4.4.3 Bexarotene
4.5 Schizophrenia Therapeutics Market-Clinical Pipeline by Mechanism of Action
4.6 Schizophrenia Pipeline-Pipeline by Clinical Phases of Development
4.6.1 Schizophrenia Therapeutics-Regulatory and Phase III Clinical Pipeline
4.6.2 Schizophrenia Therapeutics-Phase II Clinical Pipeline
4.6.3 Schizophrenia Therapeutics-Phase I Clinical Pipeline
4.6.4 Schizophrenia Therapeutics-Preclinical and Discovery Pipeline
4.7 Key Takeaway
4.8 Discontinued/Suspended Drugs for Schizophrenia
5 Schizophrenia Market: Implications for Future Market Competition
6 Schizophrenia Market: Future Players in Schizophrenia Market
6.1 Introduction
6.2 GlaxoSmithKline
6.2.1 Overview
6.2.2 CNS Portfolio
6.2.3 Schizophrenia Product Portfolio
6.3 Johnson & Johnson
6.3.1 Overview
6.3.2 CNS Portfolio
6.3.3 Schizophrenia Product Portfolio
6.4 Pfizer
6.4.1 Overview
6.4.2 CNS Portfolio
6.4.3 Schizophrenia Product Portfolio
6.5 AstraZeneca
6.5.1 Overview
6.5.2 CNS Portfolio
6.5.3 Schizophrenia Product Portfolio
6.6 Merck & Co.
6.6.1 Overview
6.6.2 CNS Portfolio
6.6.3 Schizophrenia Product Portfolio
7 Schizophrenia Market: Appendix
7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panels Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

List of Tables
1.1 List of Tables
Table 1: Global Schizophrenia-Bipolar Therapeutics Market, Revenue ($bn), 2000-2008
Table 2: Global Schizophrenia-Bipolar Therapeutics Market, Revenue ($bn), 2009-2015
Table 3: Major Marketed Products Comparison in Schizophrenia Market, 2009
Table 4: Schizophrenia Therapeutics-Most Promising Drugs Under Clinical Development, 2009
Table 5: Schizophrenia Therapeutics-Phase III Clinical Pipeline, 2009
Table 6: Schizophrenia Therapeutics-Phase II Clinical Pipeline, 2009
Table 7: Schizophrenia  Therapeutics-Phase I Clinical Pipeline, 2009
Table 8: Schizophrenia  Therapeutics-Preclinical and Discovery Pipeline, 2009
Table 9: List of Discontinued Drugs for Schizophrenia, 2009
Table 10: GlaxoSmithKline-CNS Marketed Products, 2009
Table 11: GlaxoSmithKline-CNS Pipeline Products, 2009
Table 12: Johnson & Johnson-CNS Marketed Products, 2009
Table 13: Johnson & Johnson-CNS Pipeline Products, 2009
Table 14: Pfizer-CNS Marketed Products, 2009
Table 15: Pfizer-CNS Pipeline Products, 2009
Table 16: AstraZeneca-CNS Marketed  Products, 2009
Table 17: Astra Zeneca-CNS Pipeline Products, 2009
Table 18: Merck & Co.-CNS Marketed Products, 2009
Table 19: Merck & Co.-CNS Pipeline Products, 2009

List of Figures
1.2 List of Figures
Figure 1: Global Schizophrenia-Bipolar Market Revenue ($m), 2000-2015
Figure 2: Opportunity and Unmet Need in the Schizophrenia Market, 2009
Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Schizophrenia, 2009
Figure 4: Technology Trends Analytic Framework of the Schizophrenia Pipeline, 2009
Figure 5: Technology Trends Analytic Framework of the Schizophrenia Pipeline-Description, 2009
Figure 6: Schizophrenia Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2009
Figure 7: Schizophrenia Pipeline by Phase of Clinical Development, 2009
Figure 8: Implications for Future Market Competition in the Schizophrenia, 2009
Figure 9: Schizophrenia Therapeutics Market-Clinical Pipeline by Company, 2009
Figure 10: GlobalData Methodology, 2009
Figure 11: GlobalData  Market Forecasting Model